Latest news
Ascletis Begins Phase I Studies of Amylin Agonist ASC36 and Its GLP-1/GIP Co-Formulation for Obesity - BioPharm InternationalBioPharm International · Mon, 10 Aug 2026 19:50:09 GMTAscletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide - PR NewswirePR Newswire · Mon, 10 Aug 2026 11:00:00 GMTAscletis receives FDA clearance to begin Phase III ASC30 programme - Clinical Trials ArenaClinical Trials Arena · Tue, 04 Aug 2026 10:29:25 GMTIs Ascletis’ Biologic Obesity Pipeline Altering The Investment Case For Ascletis Pharma (SEHK:1672)? - simplywall.stsimplywall.st · Mon, 03 Aug 2026 17:24:29 GMTAscletis Pharma Gets US FDA Nod for Phase III Trial of Obesity Drug Candidate - MoomooMoomoo · Mon, 03 Aug 2026 12:47:46 GMTAscletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination - PR NewswirePR Newswire · Mon, 03 Aug 2026 10:55:00 GMTAscletis Pharma, Inc. Revenue Breakdown – HKEX:1672 - TradingViewTradingView · Sat, 01 Aug 2026 05:43:24 GMT